PE20190845A1 - Metodos para determinar resistencia a terapia de receptor de androgeno - Google Patents

Metodos para determinar resistencia a terapia de receptor de androgeno

Info

Publication number
PE20190845A1
PE20190845A1 PE2019001034A PE2019001034A PE20190845A1 PE 20190845 A1 PE20190845 A1 PE 20190845A1 PE 2019001034 A PE2019001034 A PE 2019001034A PE 2019001034 A PE2019001034 A PE 2019001034A PE 20190845 A1 PE20190845 A1 PE 20190845A1
Authority
PE
Peru
Prior art keywords
androgen receptor
methods
polypeptide
determine resistance
receptor therapy
Prior art date
Application number
PE2019001034A
Other languages
English (en)
Spanish (es)
Inventor
James David Joseph
Jeffrey H Hager
John Lee Sensintaffar
Nhin Lu
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of PE20190845A1 publication Critical patent/PE20190845A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
PE2019001034A 2012-07-27 2013-07-26 Metodos para determinar resistencia a terapia de receptor de androgeno PE20190845A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261676842P 2012-07-27 2012-07-27
US201361783763P 2013-03-14 2013-03-14
US201361829123P 2013-05-30 2013-05-30
PCT/US2013/052395 WO2014018926A1 (en) 2012-07-27 2013-07-26 Methods and compositions for determining resistance to androgen receptor therapy

Publications (1)

Publication Number Publication Date
PE20190845A1 true PE20190845A1 (es) 2019-06-17

Family

ID=48948536

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015000095A PE20150644A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
PE2019000439A PE20190574A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
PE2019001034A PE20190845A1 (es) 2012-07-27 2013-07-26 Metodos para determinar resistencia a terapia de receptor de androgeno

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2015000095A PE20150644A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
PE2019000439A PE20190574A1 (es) 2012-07-27 2013-07-26 Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno

Country Status (34)

Country Link
US (2) US9617602B2 (enExample)
EP (2) EP2877599B1 (enExample)
JP (3) JP6297556B2 (enExample)
KR (2) KR102210183B1 (enExample)
CN (3) CN108048567A (enExample)
AU (3) AU2013295543B2 (enExample)
BR (2) BR112015001801A2 (enExample)
CA (1) CA2879926A1 (enExample)
CL (1) CL2015000194A1 (enExample)
CO (1) CO7280477A2 (enExample)
CR (1) CR20150022A (enExample)
CY (1) CY1122651T1 (enExample)
DK (1) DK2877599T3 (enExample)
EA (2) EA035535B1 (enExample)
EC (1) ECSP15007420A (enExample)
ES (1) ES2764381T3 (enExample)
GT (1) GT201500019A (enExample)
HR (1) HRP20192342T1 (enExample)
HU (1) HUE047781T2 (enExample)
IL (2) IL236844B (enExample)
LT (1) LT2877599T (enExample)
MX (2) MX370507B (enExample)
NI (1) NI201500004A (enExample)
NZ (4) NZ740700A (enExample)
PE (3) PE20150644A1 (enExample)
PH (2) PH12015500175B1 (enExample)
PL (1) PL2877599T3 (enExample)
PT (1) PT2877599T (enExample)
RS (1) RS59812B1 (enExample)
SG (2) SG10201703254VA (enExample)
SI (1) SI2877599T1 (enExample)
SM (1) SMT201900735T1 (enExample)
UA (1) UA118178C2 (enExample)
WO (1) WO2014018926A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
MD20140054A2 (ro) 2011-12-16 2014-10-31 Olema Pharmaceuticals, Inc. Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
CA2870679A1 (en) 2012-04-20 2013-10-24 Cepheid Methods of detecting bladder cancer
WO2014066864A2 (en) * 2012-10-26 2014-05-01 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
EP2959013A2 (en) * 2013-02-25 2015-12-30 Novartis AG Novel androgen receptor mutation
EP2964786B1 (en) * 2013-03-06 2018-12-19 Cepheid Methods of detecting bladder cancer
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2015215000B2 (en) * 2014-02-05 2017-10-19 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
CA3018351C (en) 2016-03-29 2024-02-13 F. Hoffmann-La Roche Ag Method of operating a receiver for receiving analyte data, receiver and computer program product
WO2017181161A1 (en) * 2016-04-15 2017-10-19 Predicine, Inc. Systems and methods for detecting genetic alterations
CN106405085B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106290919B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106198985B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
CN106526185B (zh) * 2016-10-28 2018-03-30 拜尔康(天津)医药科技有限公司 用于检测去势抵抗性前列腺癌的elisa试剂盒及检测方法
US10933059B2 (en) * 2016-12-16 2021-03-02 Kangpu Biopharmaceuticals. Ltd. Combination, application thereof and treatment method
KR20200074950A (ko) * 2017-10-19 2020-06-25 예일 유니버시티 약초 추출물 및 이의 조성물에 의한 안드로겐 수용체의 억제
CN108018342A (zh) * 2017-12-04 2018-05-11 合肥艾迪康临床检验所有限公司 检测ar基因突变的引物和方法
CN109115742A (zh) * 2018-09-05 2019-01-01 中国农业科学院农业质量标准与检测技术研究所 一种抗雄激素效应的检测方法
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
WO2021061642A1 (en) * 2019-09-23 2021-04-01 Accutar Biotechnology Inc. Novel ureas having androgen receptor degradation activity and uses thereof
GB201914296D0 (en) * 2019-10-03 2019-11-20 Univ Oxford Innovation Ltd Treatment
WO2021110731A1 (en) * 2019-12-03 2021-06-10 Bayer Aktiengesellschaft Method for determining the response of prostate cancer patients to treatment with androgen receptor antagonists based on gene expression changes or super-enhancer protein-binding profiles
CN113533730B (zh) * 2021-07-23 2022-09-06 南方医科大学深圳医院 一种血浆外泌体标志物组合及其应用
WO2024001989A1 (en) * 2022-06-27 2024-01-04 Etern Biopharma (Shanghai) Co., Ltd. Compositions and methods for modulating molecules
CN117860773B (zh) * 2023-11-28 2024-07-16 四川大学华西医院 促进ar基因甲基化的药物及其在预防或治疗雄性激素脱发中的用途
CN117778322B (zh) * 2023-12-17 2025-02-07 苏州拓维生物技术有限公司 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用
CN119979543B (zh) * 2025-04-14 2025-07-22 羿美诚健(上海)生物医药有限公司 靶向雄激素受体的小核酸及其药物组合物和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0714410A4 (en) 1993-07-26 1997-08-20 K O Technology Inc GENE ALTERNATIVE ALLEH INHIBITORS USED AS A BASE FOR THERAPEUTIC AGENTS AGAINST CANCER
US6200754B1 (en) 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes
GB0005689D0 (en) * 2000-03-09 2000-05-03 Schering Ag Crystal
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
MX2010005703A (es) * 2007-11-26 2010-06-11 Enzon Pharmaceuticals Inc Antagonistas de acido nucleico entrelazado que eligen como objetivo al receptor de androgeno.
EP2065474A1 (en) 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
US8133724B2 (en) * 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
CN102388106B (zh) * 2009-04-03 2014-04-23 巴斯夫欧洲公司 制备复合材料的方法
AU2010310477A1 (en) * 2009-10-23 2012-05-03 Health Research Inc. Method for treating androgen receptor positive cancers

Also Published As

Publication number Publication date
MX2019015148A (es) 2020-02-19
BR112015001801A2 (pt) 2017-11-07
JP2018113968A (ja) 2018-07-26
EA201590290A1 (ru) 2015-06-30
PL2877599T3 (pl) 2020-05-18
CO7280477A2 (es) 2015-05-29
MX370507B (es) 2019-12-16
EA029563B1 (ru) 2018-04-30
PH12015500175A1 (en) 2015-03-16
ECSP15007420A (es) 2016-01-29
NZ744288A (en) 2020-04-24
SMT201900735T1 (it) 2020-03-13
NZ704487A (en) 2018-05-25
AU2019201726B2 (en) 2021-04-01
CR20150022A (es) 2015-04-30
HUE047781T2 (hu) 2020-05-28
IL236844A0 (en) 2015-03-31
NI201500004A (es) 2015-10-05
EA035535B1 (ru) 2020-07-01
IL265610A (en) 2019-05-30
EP2877599B1 (en) 2019-10-23
HK1211060A1 (en) 2016-05-13
SG11201500184TA (en) 2015-04-29
AU2017203385B2 (en) 2018-12-20
KR20150072399A (ko) 2015-06-29
EP2877599A1 (en) 2015-06-03
CL2015000194A1 (es) 2015-04-24
CN108048567A (zh) 2018-05-18
UA118178C2 (uk) 2018-12-10
NZ740700A (en) 2019-07-26
AU2017203385A1 (en) 2017-06-08
JP2020072655A (ja) 2020-05-14
RS59812B1 (sr) 2020-02-28
US20170196840A1 (en) 2017-07-13
WO2014018926A1 (en) 2014-01-30
EA201792520A2 (ru) 2018-04-30
US9617602B2 (en) 2017-04-11
CY1122651T1 (el) 2021-03-12
JP6297556B2 (ja) 2018-03-20
EP3653733A1 (en) 2020-05-20
KR102210183B1 (ko) 2021-01-29
IL236844B (en) 2019-09-26
US20150252426A1 (en) 2015-09-10
BR122017017921A2 (pt) 2019-09-10
PE20150644A1 (es) 2015-05-11
PE20190574A1 (es) 2019-04-22
DK2877599T3 (da) 2020-01-20
PT2877599T (pt) 2020-01-24
EA201792520A3 (ru) 2018-08-31
LT2877599T (lt) 2020-01-27
ES2764381T3 (es) 2020-06-03
AU2013295543A1 (en) 2015-02-05
CN110845626A (zh) 2020-02-28
SG10201703254VA (en) 2017-06-29
NZ742581A (en) 2020-02-28
CN104685072A (zh) 2015-06-03
JP6592545B2 (ja) 2019-10-16
KR20210012064A (ko) 2021-02-02
PH12015500175B1 (en) 2015-03-16
JP2015531590A (ja) 2015-11-05
CA2879926A1 (en) 2014-01-30
SI2877599T1 (sl) 2020-03-31
AU2019201726A1 (en) 2019-04-04
PH12018502500A1 (en) 2020-09-14
WO2014018926A8 (en) 2014-04-10
IL265610B (en) 2021-03-25
HRP20192342T1 (hr) 2020-04-03
MX2015001209A (es) 2015-09-23
GT201500019A (es) 2017-07-24
AU2013295543B2 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
PE20190845A1 (es) Metodos para determinar resistencia a terapia de receptor de androgeno
TN2015000085A1 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
BR112014019901A8 (pt) Proteínas de fator viii recombinante
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
JP2013172734A5 (enExample)
MX2016011580A (es) Dominios de fibronectina tipo iii que se unen a albumina de suero.
BR112014020694A2 (pt) proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201008682D0 (en) Epitope tag for affinity based applications
WO2014160490A8 (en) Antibody formulations
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MX356162B (es) Sistema de expresion y secrecion.
JP2015524403A5 (enExample)
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2013010392A (es) Proteinas de fusion npp1.
JP2016520531A5 (enExample)
HK1215441A1 (zh) 人血清白蛋白结合化合物及其融合蛋白
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
WO2015015516A3 (en) Expression vector for production of recombinant proteins in prokaryotic host cells
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
HK1203983A1 (en) Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
WO2015134833A3 (en) Therapeutic proteins for treating cancers and methods for using such proteins
IN2014MN00935A (enExample)
TH174396A (th) พอลิเพพไทด์ที่ประกอบด้วย Fc ที่มีไกลโคสิเลชันที่ได้รับการแปรเปลี่ยน และลดการทำงานของเอฟเฟคเตอร์
TH170760A (th) แอนติเจนที่ทำปฏิกิริยาในวงกว้างที่มีการเพิ่มประสิทธิภาพโดยการคำนวณสำหรับ ไข้หวัดใหญ่ h1n1